Fabre-Kramer Pharmaceuticals

This article relies excessively on references to primary sources. Please improve this article by adding secondary or tertiary sources.
Find sources: "Fabre-Kramer Pharmaceuticals" – news · newspapers · books · scholar · JSTOR (August 2016) (Learn how and when to remove this message)

|

Fabre-Kramer Pharmaceuticals

Company type| S Corporation
Industry| Pharmaceuticals
Founded| 1992
Headquarters| Houston, Texas

Key people

| Stephen Kramer (CEO) Ed Koehler (Executive Vice President, CFO)
Products| Travivo (Gepirone ER), FKB01MD, FKW00GA, FKF02SC, FKK01PD
Website| www.fabrekramer.com

Fabre-Kramer Pharmaceuticals is a pharmaceutical company that specializes in the development of psychotropic drugs. Products in their current development pipeline include gepirone and FKB01MD for major depression, gepirone and FKW00GA for social anxiety disorder,[1] gepirone for hypoactive sexual desire disorder, FKF02SC for schizophrenia, and FKK01PD for Parkinson's disease.[2]

The company has also conducted clinical studies on a gepirone extended release formulation for major depression.[3][4][5]

In 2007, Fabre-Kramer Pharmaceuticals along with GlaxoSmithKline (GSK) received a 'not approvable' letter from the US Food and Drug Administration, for a gepirone extended release drug, an antidepressant treatment for adults.[6]

## References

[edit]

1. ^ "Pipeline – Fabre-Kramer Pharmaceuticals, Inc". Archived from the original on March 30, 2023. Retrieved 2023-03-30.
2. ^ "Product Pipeline". Fabre Kramer Pharmaceuticals. Archived from the original on 2011-11-11. Retrieved 2011-10-16.
3. ^ Fabre LF, Smith LC (August 2011). "The Effect of Major Depression on Sexual Function in Women". J Sex Med. 9 (1): 231–9\. doi:10.1111/j.1743-6109.2011.02445.x. PMID 21883948.
4. ^ Fabre LF, Smith LC, DeRogatis LR (September 2011). "Gepirone-ER treatment of low sexual desire associated with depression in women as measured by the DeRogatis Inventory of Sexual Function (DISF) fantasy/cognition (desire) domain--a post hoc analysis". J Sex Med. 8 (9): 2569–81\. doi:10.1111/j.1743-6109.2011.02330.x. PMID 21707926.
5. ^ Fabre LF, Brown CS, Smith LC, Derogatis LR (May 2011). "Gepirone-ER treatment of hypoactive sexual desire disorder (HSDD) associated with depression in women". J Sex Med. 8 (5): 1411–9\. doi:10.1111/j.1743-6109.2011.02216.x. PMID 21324094.
6. ^ Lewcock, Anna (November 5, 2007). "GSK, Fabre-Kramer lose out on antidepressant". outsourcing-pharma.com. Archived from the original on September 10, 2023. Retrieved 2020-05-11.

## External links

[edit]

* Fabre-Kramer Pharmaceuticals, Inc

This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.

|

* v
* t
* e

*[v]: View this template
*[t]: Discuss this template
*[e]: Edit this template